Mayo Clinic's Zombie Cell Studies
Not all aging cells cause the same harm, and scientists now have better ways to tell them apart. A set of seven Mayo Clinic studies shows that senescent, or “zombie,” cells form many distinct types. The papers trace how these cells fuel inflammation and test ways to rein them in.
Avin CP via Unsplash, free license
Key Takeaways
- Senescent cells vary by tissue and by the pathway that created them, and a new SenMayo gene set helps identify them across tissues and models.
- Damaged mitochondria drive inflammation by leaking DNA and RNA into the cell and by changing how inflammatory genes switch on.
- The team proposes IL-23R as a blood biomarker of aging and found that tomatidine, a compound from tomatoes, improved cognition in aged mice; all results are preclinical.
Many Kinds of Zombie
Senescent cells stop dividing but stay alive and active. They release inflammatory molecules linked to age-related disease. Young immune systems clear them. With age, they pile up.
Spotting them has been one of the field's hardest problems. The Mayo studies show they are not a single population. Their behavior depends on the tissue they occupy and the biological pathway that pushed them into senescence.
The SenMayo gene set gives researchers a consistent way to find these cells across tissues and experimental models. A related paper defines “senotypes,” while another compares p16- and p21-positive cells across human and mouse tissues.
“This body of work is moving the aging field forward to precisely identify, understand and target the specific senescent cells that contribute to age-related dysfunction, which is the necessary groundwork to develop new therapies that support healthy aging,” said Marissa Schafer, a Mayo Clinic researcher whose lab led several of the studies.
Two Leaks, One Fire
Several papers focus on mitochondria, the structures that produce a cell's energy. When they malfunction, they drive inflammation in two ways.
First, mitochondrial DNA and RNA escape into the main body of the cell. There, they trip immune sensors meant to detect viruses. In one study, mitochondrial RNA leaked through pores opened by the proteins BAX and BAK and activated the sensors RIG-I and MDA5. Blocking that route cut inflammation in a mouse model of severe fatty liver disease.
Second, altered mitochondrial metabolism produces more acetyl-CoA. That molecule supports epigenetic changes that make inflammatory genes easier to switch on. Together, the leaked molecules raise the alarm while the metabolic shift unlocks the genes.
This points to a different kind of treatment. Instead of killing senescent cells, drugs might quiet the specific pathways that make them harmful.
A Blood Test for Aging
One study proposes IL-23R as a marker of biological aging. The protein normally alerts immune cells to fight infection, but overactive signaling can damage tissue.
In blood from 40 men and 40 women aged 20 to 90, IL-23R levels rose with age. In mice, the protein tracked markers of senescence in aged organs, especially the kidneys. It also fell after treatment with drugs that target senescent cells.
Tomatoes and Older Brains
Other studies tested interventions in aged mice: senolytic drugs, genetic approaches and tomatidine, a compound found in tomatoes. These strategies reduced inflammation and improved measures of frailty, brain inflammation and cognitive performance. One paper mapped senescent and disease-linked microglia in the white matter of aged mouse brains.
The research forms part of the NIH-funded Cellular Senescence Network, or SenNet, which aims to build atlases of senescent cells across the human lifespan. None of the findings have been tested as treatments in people.
From Killing Cells to Measuring Them
Early senolytic research focused on clearing zombie cells wholesale. These papers push the field toward measurement first: identifying which cells matter and tracking them in blood. A reliable biomarker could make human trials of anti-aging drugs far easier, because researchers could see effects without waiting decades for disease outcomes. Mayo's earlier IL-23R biomarker work showed the protein dropped after senotherapeutic treatment, which is exactly the kind of signal such trials need. Other groups are working on related ideas, including findings on low-dose aspirin and dementia risk.
The mitochondrial findings also tie aging to diseases beyond old age. The Nature Communications paper on leaking mitochondrial RNA linked the pathway to fatty liver disease, a growing health burden worldwide. As gene-level tools mature, with prime editing now used inside a patient's body, researchers hope to translate cell-level maps like these into targeted therapies, though that remains years away.
Written by Vytautas Valinskas